These molecules bind to a specific region on Ras that was previously known but not fully exploited, and by modifying the pocket, they can block many cancer-causing Ras mutations—not just one specific type.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether inhibitors targeting the enlarged switch I–II pocket improve outcomes across multiple KRas mutation subtypes compared to mutation-specific inhibitors.
A systematic review and meta-analysis of all clinical trials evaluating Ras inhibitors targeting the switch I–II pocket, comparing response rates and survival across KRasG12D, G12V, G13D, Q61H, and other non-G12C mutants versus G12C-specific inhibitors.
Whether a switch I–II pocket inhibitor improves survival in patients with non-G12C KRas mutations compared to standard therapy.
A double-blind, randomized phase II trial of 120 patients with advanced KRas-mutant cancers excluding G12C (e.g., G12D, G12V, Q61H), randomized to receive the lead inhibitor or standard chemotherapy, with primary endpoint of progression-free survival and mandatory tumor sequencing at baseline and progression.
Whether patients with non-G12C KRas mutations respond to switch I–II pocket inhibitors at similar rates to those with G12C mutations.
A prospective cohort study of 200 patients with KRas-mutant cancers (50 each for G12C, G12D, G12V, Q61H) receiving a switch I–II pocket inhibitor, measuring tumor response by RECIST 1.1 and correlating response with mutation subtype.
Whether tumors with non-G12C mutations are more likely to respond to switch I–II pocket inhibitors than to G12C-specific inhibitors.
A matched case-control study comparing 60 responders to switch I–II inhibitors (all non-G12C) with 60 non-responders to G12C inhibitors, matched for tumor type and stage, analyzing mutation status and inhibitor binding profile.
Whether the switch I–II pocket is structurally accessible in multiple KRas mutants beyond G12C.
A cross-sectional analysis of crystal structures or cryo-EM models of 15 different oncogenic KRas mutants (G12C, G12D, G12V, Q61H, etc.) bound to the inhibitor, measuring pocket volume, hydrogen bonding, and hydrophobic interactions to assess structural compatibility.